Compare · NEOG vs ORKA
NEOG vs ORKA
Side-by-side comparison of Neogen Corporation (NEOG) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NEOG and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG carries a market cap of $3.78B.
- Over the past year, NEOG is up 85.4% and ORKA is up 568.3% - ORKA leads by 482.9 points.
- NEOG has been more active in the news (7 items in the past 4 weeks vs 5 for ORKA).
- ORKA has more recent analyst coverage (11 ratings vs 5 for NEOG).
- Company
- Neogen Corporation
- Oruka Therapeutics Inc.
- Price
- $9.53+1.82%
- $68.97+2.03%
- Market cap
- $3.78B
- -
- 1M return
- +4.04%
- +57.38%
- 1Y return
- +85.41%
- +568.31%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1989
- News (4w)
- 7
- 5
- Recent ratings
- 5
- 11
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Latest NEOG
- Neogen's Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification
- Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 3 filed by new insider Stacey Jennifer Evans
- SEC Form 10-Q filed by Neogen Corporation
- Neogen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Neogen Reports Third Quarter Fiscal Year 2026 Financial Results
- Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary
- Neogen Corporation filed SEC Form 8-K: Leadership Update
- Neogen to Release Third-Quarter Fiscal Year 2026 Financial Results on April 9, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Neogen Corporation
Latest ORKA
- SEC Form 424B7 filed by Oruka Therapeutics Inc.
- SEC Form DEFA14A filed by Oruka Therapeutics Inc.
- SEC Form DEF 14A filed by Oruka Therapeutics Inc.
- SEC Form 4 filed by Goncalves Joana
- SEC Form EFFECT filed by Oruka Therapeutics Inc.
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Oruka Therapeutics Inc.
- Chief Executive Officer Klein Lawrence Otto sold $71,408 worth of shares (1,729 units at $41.30), decreasing direct ownership by 0.19% to 927,309 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $16,313 worth of shares (395 units at $41.30), decreasing direct ownership by 2% to 18,863 units (SEC Form 4)
- Chief Operating Officer Sandler Laura Lee sold $24,780 worth of shares (600 units at $41.30), decreasing direct ownership by 0.25% to 236,984 units (SEC Form 4)